
The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …

NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

